Table 1 FDA-approved CAR-T products
From: CAR-T cell potency: from structural elements to vector backbone components
Generic Name | Tisagenlecleucel | Axicabtagene ciloleucel | Brexucabtagene autoleucel | Lisocabtagene maraleucel | Idecabtagene vicleucel | Ciltacabtagene autoleucel |
|---|---|---|---|---|---|---|
Trade name | KYMRIAH™ | YESCARTA™ | TECARTUS™ | BREYANZI® | ABECMA® | CARVYKTI |
Company | Novartis | Gilead/Kite | Gilead/Kite | Bristol-Myers Squibb | Bristol-Myers Squibb | Janssen-Cilag International NV |
Approval date | Aug-2017 | Oct-2017 | Jul-2020 | Feb-2021 | Mar-2021 | Feb-2022 |
Target patients | R/R B-ALL R/R DLBCL | R/R DLBCL R/R NHL | R/R MCL | R/R LBCL | R/R MM | R/R MM |
Targeted antigen | CD19 | CD19 | CD19 | CD19 | BCMA | BCMA |